These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 29454647)

  • 1. Dynamic plasticity of macrophage functions in diseased liver.
    Ritz T; Krenkel O; Tacke F
    Cell Immunol; 2018 Aug; 330():175-182. PubMed ID: 29454647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting hepatic macrophages to treat liver diseases.
    Tacke F
    J Hepatol; 2017 Jun; 66(6):1300-1312. PubMed ID: 28267621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophages in metabolic associated fatty liver disease.
    Alharthi J; Latchoumanin O; George J; Eslam M
    World J Gastroenterol; 2020 Apr; 26(16):1861-1878. PubMed ID: 32390698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of hepatic macrophages in liver metastasis.
    Keirsse J; Van Damme H; Geeraerts X; Beschin A; Raes G; Van Ginderachter JA
    Cell Immunol; 2018 Aug; 330():202-215. PubMed ID: 29661474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD).
    Kragh Petersen S; Bilkei-Gorzo O; Govaere O; Härtlova A
    Scand J Immunol; 2020 Nov; 92(5):e12971. PubMed ID: 32892401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease.
    Chen S; Guo H; Xie M; Zhou C; Zheng M
    Int Immunopharmacol; 2021 Aug; 97():107609. PubMed ID: 33887577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Multifaceted Roles of Macrophages in NAFLD Pathogenesis.
    Vonderlin J; Chavakis T; Sieweke M; Tacke F
    Cell Mol Gastroenterol Hepatol; 2023; 15(6):1311-1324. PubMed ID: 36907380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities.
    Wen Y; Lambrecht J; Ju C; Tacke F
    Cell Mol Immunol; 2021 Jan; 18(1):45-56. PubMed ID: 33041338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage heterogeneity in liver injury and fibrosis.
    Tacke F; Zimmermann HW
    J Hepatol; 2014 May; 60(5):1090-6. PubMed ID: 24412603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases.
    van der Heide D; Weiskirchen R; Bansal R
    Front Immunol; 2019; 10():2852. PubMed ID: 31849997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis.
    Li H; Zhou Y; Wang H; Zhang M; Qiu P; Zhang M; Zhang R; Zhao Q; Liu J
    Front Immunol; 2020; 11():1169. PubMed ID: 32670278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.
    Oniciu DC; Hashiguchi T; Shibazaki Y; Bisgaier CL
    PLoS One; 2018; 13(5):e0194568. PubMed ID: 29847555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophages as key regulators of liver health and disease.
    Papachristoforou E; Ramachandran P
    Int Rev Cell Mol Biol; 2022; 368():143-212. PubMed ID: 35636927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic macrophages: Key players in the development and progression of liver fibrosis.
    Cheng D; Chai J; Wang H; Fu L; Peng S; Ni X
    Liver Int; 2021 Oct; 41(10):2279-2294. PubMed ID: 33966318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis.
    An P; Wei LL; Zhao S; Sverdlov DY; Vaid KA; Miyamoto M; Kuramitsu K; Lai M; Popov YV
    Nat Commun; 2020 May; 11(1):2362. PubMed ID: 32398673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophages in Nonalcoholic Fatty Liver Disease: A Role Model of Pathogenic Immunometabolism.
    Krenkel O; Tacke F
    Semin Liver Dis; 2017 Aug; 37(3):189-197. PubMed ID: 28847030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.